ISHL10 Videos

Movie: A History of Hodgkin Lymphoma

Case Discussion #1: Early Unfavorable - PET driven?

Marc André

Case Discussion #2: HL during pregnancy

Ranjana Advani

Case Discussion #3: Late Relapse of HL

Paul J. Bröckelmann

Clinical – IPS and other scores

Jonathan Friedberg

Serum marker

Arjan Diepstra

Circulating cell-free DNA in HL

Peter Vandenberghe

Plasma vesicle-associated miRNAs as therapy response biomarkers in Hodgkin Lymphoma

Michiel Pegtel

Mid-treatment TARC and mid-treatment FDG-PET predict for progression free survival in classical Hodgkin Lymphoma

Wouter Plattel

A comprehensive analysis of Hodgkin Lymphoma seasonality across various geographic regions

Sven Borchmann

Genetic lesions in HRS cells and their relationship to CD30+ B cells

Ralf Küppers

Exome-sequencing in HL

Enrico Tiacci

Gene expression pro ling of the HL microenvironment

Christian Steidl

Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS

Juan F García

High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma

Peter Hollander

Other new approaches

Anke van den Berg

The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma

Anna Lollies

Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion

Frederik Wein

CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro- tumor e ects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment

Naike Casagrande

Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?

Arjan Diepstra

PET update 2016

Bruce Cheson

WS report “Is PET as good as we think?”

Michel Meignan

Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and prognostic impact in Hodgkin Lymphoma: results from an international collaborative study

Collette Zwarthoed

Strong predictive value of PET based metabolic tumor volume on survival after autologous HCT for Hodgkin Lymphoma

Vit Prochazka

Semi-quantitative parameters to improve the interim FDG-PET / CT positive predictive value in Hodgkin Lymphoma

Stefan Hohaus

Early favorable HL: pros and cons of PET-adapted therapy

Martin Hutchings

Early unfavorable: new standard of care?

John Raemaekers

NLPHL

Dennis Eichenauer

Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial

Stephanie Sasse

Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience

Results of US intergroup trial of response-adapted chemotherapy or chemotherapy / radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB / Alliance 50604)

David Straus

Panelists

Craig H. Moskowitz, Graham Collins, Catherine Diefenbach, Vincent Ribrag

Interim results of EuroNet-PHL-C1

Judith Landman-Parker

Targeted agents in pediatric HL

Monika Metzger

COG / ECOG: AYA HL

Kara Kelly

Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/ A12707)

Stephen Daw

Phase III ABC study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children's Oncology Group

Kara Kelly

Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis

Andrew Evens

Debate: PET-guided ABVD versus old school BEACOPP

Anton Hagenbeek, Peter Johnson, Peter Borchmann

Perspectives in advanced HL

Pauline Brice

BEACOPPescalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials

Bastian von Tresckow

Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials

Marc André

Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging,

Jonathan Friedberg

Brentuximab vedotin in relapsed HL

Craig H. Moskowitz

Clinical results with anti-PD(L)1 antibodies in HL

Philippe Armand

CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation

Pier Luigi Zinzani

Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study

Craig H. Moskowitz

TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study

Anton Hagenbeek

Fatigue

Steffanie Kreissl

Survivorship surveillance

Alexander Fosså

Second malignancies

Flora van Leeuwen

Patient preferences – survey of HL survivors on treatment associated burdens and side effects

Carolin Bürkle

Change in peripheral blood lymphocyte telomere length in relation to mortality and morbidity in Hodgkin Lymphoma patients

Radhia M'kacher

The impact of treatment type and age on ovarian toxicity in the RATHL study

RA Anderson